Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from PBMs

Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound

Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.

Benzinga

Reform Refill: Has Scott Wiener Convinced Gov. Newsom to Rein in Prescription Middlemen?

Why a state senator may finally win his battle against powerful pharmacy benefit managers.

Capital & Main

How Democrats can pull off a win now

There is no need to wait for the next election

Salon

From analysis to the latest developments in health,
read the most diverse news in one place.

Trump has promised to 'knock out' pharmacy benefit managers. How the drug middlemen became a $557 billion industry that its customers love to hate

The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Fortune

FTC Report Reveals Pbms Inflated Drug Prices For Profit

FTC report exposes PBMs inflating drug prices, sparking debate on industry oversight.

Top News

GOP Spending Bill Excludes Major Changes To Pharmacy Benefit Managers

GOP spending bill proposal excludes reforms for pharmacy benefit managers (PBMs) despite bipartisan expectations.

Top News

What are pharmacy benefit managers? A health economist explains how lack of competition drives up drug prices for everyone

Wegovy and Ozempic are weight loss drugs that promise to transform the treatment of obesity, heart disease and other chronic conditions that afflict millions of Americans. But while everyone agrees these drugs have the potential to transform lives, no one can agree on how best to pay for them.

The Conversation

Read news from The Economist, FT, and more,
with one subscription

Kentucky attorney general targets another big pharmacy benefit manager in opioid-related lawsuit

Kentucky’s attorney general has expanded an opioid-related lawsuit to target another pharmacy benefit manager

The Independent UK

Outgoing Congress Still Has Time To Act On PBM Reform

Congress and President Joe Biden can address the problem of PBMs -- Pharmacy Benefit Managers -- by passing two bipartisan reforms during the current "lame duck" legislative session.

International Business Times

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Fortune

FTC Sues Pbms Over Soaring Insulin Prices

FTC lawsuit targets major PBMs for inflating insulin prices, impacting patients and drug costs. Debate over drug pricing and PBM role in healthcare system ...

Top News

High insulin prices spur a federal lawsuit against three pharmacy benefit managers

The federal government is suing some pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for patients

The Independent UK

TRICARE becomes part of fight over pharmacy benefit managers - Roll Call

Lawmakers question whether the decision to renew Express Scripts as TRICARE's pharmacy benefit manager is a wise decision.

Roll Call

Biden's plan to save money on Medicare drugs risks leaving shelves empty, pharmacists say

Biden is campaigning on cutting drug costs for Medicare patients, but independent pharmacists say one strategy makes it unaffordable to keep some brand-name medicines in stock.

Fortune

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

Rural pharmacies fill a health care gap in the US. Owners say it's getting harder to stay open

Rural pharmacies can be a touchstone for their communities

Top News

US Pharmacy Benefit Managers Facing Scrutiny

Learn about the controversies surrounding US pharmacy benefit managers (PBMs) and the need for increased regulation and transparency in the healthcare system.

Fortune

Mark Cuban’s Cost Plus Drugs will begin manufacturing its own medications this week

The "Shark Tank" investor and Cost Plus Drugs cofounder Dr. Alex Oshmyansky participated in a White House health care roundtable.

Roll Call

The inescapable ad campaign for a wonky drug policy debate - Roll Call

A seven-figure, yearlong PhRMA ad campaign has taken a very wonky policy debate mainstream — and it's made a longtime actor a familiar face.

Get all your
news in one place.

100’s of premium titles.
One news app.

Kiplinger

Lawmakers Crackdown on Pharmacy Benefit Managers: The Kiplinger Letter

A crackdown on pharmacy benefit managers on drug costs might help Congress forget their differences.

Fortune

Howard Dean: 'At last, Congress proposes drug pricing reform that works'

The Patients Before Middlemen Act strikes at the heart of what makes prescription drugs so unaffordable in the U.S., according to Howard Dean.

Tribune News Service

What you need to know about the drug price fight in those TV ads

In recent months ominous ads about prescription drugs have flooded the TV airwaves. Perhaps by design, it’s not always clear who’s sponsoring the ads or why.

WEKU

What to know about the drug price fight in those TV ads

At least nine bills introduced in Congress take aim at pharmacy benefit managers, the powerful middlemen that channel prescription drugs to patients. Here's what the fuss is all about.

Tribune News Service

Will lower-cost Humira pharmaceutical options soon be available to patients?

Seven new alternatives to the high-cost Humira drug will be available in July. Some will be offered at significantly lower prices, but will patients see big savings?

Tribune News Service

Humira, the world’s top-selling drug, faces an upcoming test from low cost alternatives

If you’re one of the millions of Americans taking the prescription medication Humira, get ready to add the word biosimilars to your conversations with your doctor.

Tribune News Service

A more aggressive FTC is starting to target drug mergers and industry middlemen

Under the leadership of an aggressive opponent of anti-competitive business practices, the Federal Trade Commission is moving against drug companies and industry middlemen as part of the Biden administration’s push for lower drug prices at the pharmacy counter.

1 2

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.